The clinical value of plasma GDF-15 for prediction of lymph node metastases, prognostication and as a marker of recurrent disease, however, needs to be validated in larger patient cohorts and in clinical trials prior to potential implementation in the clinic. Here, GDF15 is linked to metastatic malignant neoplasm in the lymph nodes.